Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALKEM LABORATORIES Mar-20 |
ADCOCK INGRAM Jun-14 |
ALKEM LABORATORIES/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 2,720 | 354 | - | |
Low | Rs | 1,660 | 255 | - | |
Sales per share (Unadj.) | Rs | 697.9 | 105.2 | - | |
Earnings per share (Unadj.) | Rs | 96.1 | -26.5 | - | |
Cash flow per share (Unadj.) | Rs | 117.3 | -22.0 | - | |
Dividends per share (Unadj.) | Rs | 25.00 | 0 | - | |
Dividend yield (eoy) | % | 1.1 | 0 | - | |
Book value per share (Unadj.) | Rs | 515.2 | 82.6 | - | |
Shares outstanding (eoy) | m | 119.57 | 168.78 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 3.1 | 2.9 | 108.5% | |
Avg P/E ratio | x | 22.8 | -11.5 | -198.4% | |
P/CF ratio (eoy) | x | 18.7 | -13.9 | -134.8% | |
Price / Book Value ratio | x | 4.3 | 3.7 | 115.3% | |
Dividend payout | % | 26.0 | 0 | - | |
Avg Mkt Cap | Rs m | 261,879 | 51,396 | 509.5% | |
No. of employees | `000 | 14.3 | 4.3 | 333.8% | |
Total wages/salary | Rs m | 15,055 | 3,226 | 466.7% | |
Avg. sales/employee | Rs Th | 5,822.6 | 4,137.7 | 140.7% | |
Avg. wages/employee | Rs Th | 1,050.5 | 751.4 | 139.8% | |
Avg. net profit/employee | Rs Th | 802.0 | -1,042.6 | -76.9% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 83,444 | 17,763 | 469.8% | |
Other income | Rs m | 1,042 | 124 | 837.8% | |
Total revenues | Rs m | 84,486 | 17,888 | 472.3% | |
Gross profit | Rs m | 14,734 | -3,078 | -478.6% | |
Depreciation | Rs m | 2,528 | 767 | 329.7% | |
Interest | Rs m | 651 | 481 | 135.2% | |
Profit before tax | Rs m | 12,598 | -4,202 | -299.8% | |
Minority Interest | Rs m | 0 | -12 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,105 | 263 | 420.8% | |
Profit after tax | Rs m | 11,493 | -4,476 | -256.8% | |
Gross profit margin | % | 17.7 | -17.3 | -101.9% | |
Effective tax rate | % | 8.8 | -6.2 | -140.3% | |
Net profit margin | % | 13.8 | -25.2 | -54.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 54,960 | 13,010 | 422.4% | |
Current liabilities | Rs m | 32,433 | 7,320 | 443.1% | |
Net working cap to sales | % | 27.0 | 32.0 | 84.3% | |
Current ratio | x | 1.7 | 1.8 | 95.3% | |
Inventory Days | Days | 80 | 111 | 71.7% | |
Debtors Days | Days | 72 | 124 | 58.2% | |
Net fixed assets | Rs m | 32,710 | 7,584 | 431.3% | |
Share capital | Rs m | 239 | 82 | 289.9% | |
Net worth | Rs m | 61,607 | 13,942 | 441.9% | |
Long term debt | Rs m | 1,592 | 4,900 | 32.5% | |
Total assets | Rs m | 99,433 | 26,338 | 377.5% | |
Interest coverage | x | 20.4 | -7.7 | -263.4% | |
Debt to equity ratio | x | 0 | 0.4 | 7.4% | |
Sales to assets ratio | x | 0.8 | 0.7 | 124.4% | |
Return on assets | % | 12.2 | -15.2 | -80.5% | |
Return on equity | % | 18.7 | -32.1 | -58.1% | |
Return on capital | % | 21.0 | -19.8 | -105.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 5,851 | 1,516 | 385.9% | |
From Investments | Rs m | -7,414 | -466 | 1,592.4% | |
From Financial Activity | Rs m | 792 | 4,447 | 17.8% | |
Net Cashflow | Rs m | -731 | 5,497 | -13.3% |
Compare ALKEM LABORATORIES With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare ALKEM LABORATORIES With: ELDER PHARMA ALEMBIC PHARMA UNICHEM LAB CIPLA SANOFI INDIA
Indian share markets witnessed positive trading activity throughout the day yesterday and ended on a strong note.
Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.
An Indian company founded three decades ago in a garage caught my attention...
More